They discovered that people with both
head and neck squamous cell carcinoma
and the KRAS - variant who were treated with standard treatment, but not with cetuximab, had a higher risk of failing treatment
and developing metastatic disease, meaning the cancer spreads to distant organs
and is
incurable.